Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2010 - 2026)
Corcept Therapeutics (CORT) posted Depreciation & Amortization (CF) of $863000.0 for Q2 2026, up 44.31% sequentially from $598000.0 in Q1 2026, and up 84.01% YoY from $469000.0 in Q2 2025.
Powered by 
Analysis
Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $863000.0 in Q2 2026.
- Quarterly Depreciation & Amortization (CF) rose 84.01% year-over-year to $863000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 million (up 9.74% YoY) and the FY2025 annual result came in at $1.1 million, up 44.53% from the prior year.
- Depreciation & Amortization (CF) advanced to $863000.0 in Q2 2026 per CORT's latest filing, from $598000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $863000.0 in Q2 2026 and troughed at -$71000.0 in Q3 2025.
- A 5-year average of $317000.0 and a median of $284500.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 517.11% in 2025, down 122.33% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $660000.0 in 2022, then sank by 67.58% to $214000.0 in 2023, then jumped by 31.31% to $281000.0 in 2024, then gained by 2.85% to $289000.0 in 2025, then soared by 198.62% to $863000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $863000.0, $598000.0, and $289000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Corcept Therapeutics | 11.76 Bn | 11.46 Bn | 252.09 Mn | 863,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 863,000.00 |
| Mar 31, 2026 | 598,000.00 |
| Dec 31, 2025 | 289,000.00 |
| Sep 30, 2025 | -71,000.00 |
| Jun 30, 2025 | 469,000.00 |
| Mar 31, 2025 | 462,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Sep 30, 2024 | 318,000.00 |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 120,000.00 |
| Dec 31, 2023 | 214,000.00 |
| Sep 30, 2023 | 232,000.00 |
| Jun 30, 2023 | 424,000.00 |
| Mar 31, 2023 | 172,000.00 |
| Dec 31, 2022 | 660,000.00 |
| Sep 30, 2022 | 195,000.00 |
| Jun 30, 2022 | 116,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Dec 31, 2021 | 289,000.00 |
| Sep 30, 2021 | -1.69 Mn |